Programmed cell death-ligand 1 expression in stromal immune cells is a marker of breast cancer outcomeopen access
- Authors
- Hong, Mineui; Kim, Jeung Won; Kim, Min Kyoon; Chung, Bong Wha; Ahn, Soo Kyung
- Issue Date
- 2020
- Publisher
- IVYSPRING INT PUBL
- Keywords
- PD-L1; breast cancer; prognosis; immune-oncology; stromal immune cells
- Citation
- JOURNAL OF CANCER, v.11, no.24, pp 7246 - 7252
- Pages
- 7
- Journal Title
- JOURNAL OF CANCER
- Volume
- 11
- Number
- 24
- Start Page
- 7246
- End Page
- 7252
- URI
- https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/63620
- DOI
- 10.7150/jca.50441
- ISSN
- 1837-9664
- Abstract
- Purpose: The programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis plays an important role in antitumor immune responses. However, there is considerable inconsistency regarding the prognostic value of PD-L1 expression status in breast cancer. We sought to evaluate the differential prognostic impacts of tumoral versus stromal immune cell PD-L1 expression in primary breast cancer. Materials & Methods: Both tumoral and stromal immune PD-L1 expression in formalin-fixed, paraffin-embedded tumor samples from 233 breast cancer patients without initial stage IV metastases were evaluated by immunohistochemistry using a mouse monoclonal anti-PDL1 antibody. Clinicopathological variables were also documented. A Cox regression model was used to assess the association of tumoral/stromal immune PD-L1 expression with clinical outcome using disease-free survival (DFS) as the primary end point. Results: Both tumoral and stromal immune PD-L1 expression were associated with aggressive tumor characteristics, including higher histologic grade, as well as negative estrogen receptor, negative progesterone receptor, and positive human epithelial growth factor receptor 2 (HER2) status Multivariate analyses further demonstrated that stromal immune cell, but not tumoral, PD-L1 expression was a favorable prognostic factor for survival. Conclusions: Despite its association with aggressive tumor features, PD-L1 expression on stromal immune cells emerged as a positive prognostic biomarker in breast cancer. This pro-survival effect might reflect the presence of a strong antitumor immune response that leads to PD-L1 expression.
- Files in This Item
-
- Appears in
Collections - College of Medicine > College of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/63620)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.